A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkins Lymphoma
This research study will evaluate the safety and efficacy of a study drug called TGR-1202 in
combination with another study drug called ublituximab with or without bendamustine and
TGR-1202 alone as a possible treatment for Non-Hodgkin''s Lymphoma (NHL) that has come back or
that has not responded to standard treatment.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.